Introduction
============

Pituitary tumors represent approximately 10--15% of intracranial tumors, of which prolactin-secreting pituitary adenomas (prolactinoma) are the most common subtypes, accounting for 30--40% of pituitary tumors ([@b1-or-0-0-7173],[@b2-or-0-0-7173]). Most of these tumors are noninvasive, show slow growth and are easily treated by surgery or medical treatment, including cabergoline and dopamine agonists. However, a small subset, accounting for 2.5--10% of pituitary adenomas, are defined as aggressive pituitary tumors and can exhibit aggressive behaviors, resistance to conventional treatments and/or temozolomide (TMZ), and multiple recurrences despite standard therapies combining surgical, medical and radiotherapy treatment approaches ([@b3-or-0-0-7173],[@b4-or-0-0-7173]). Early identification of aggressive pituitary tumors is challenging but is of major clinical importance as these tumors are associated with increased morbidity and mortality ([@b5-or-0-0-7173]). Numerous studies have been performed to explore potential predictive and prognostic biomarkers for the molecular pathogenesis underlying the aggressive behavior and malignant transformation of pituitary tumors, yet research results remain fairly unreliable and controversial ([@b4-or-0-0-7173],[@b6-or-0-0-7173],[@b7-or-0-0-7173]).

MicroRNAs (miRNAs/miRs) are a large family of short endogenous noncoding RNAs, approximately 21--25 nucleotides in length, that can directly bind to the 3′-untranslated region of messenger RNA (mRNA), thereby leading to suppression of protein translation or mRNA degradation ([@b8-or-0-0-7173],[@b9-or-0-0-7173]). Subsequently, miRNAs can negatively regulate the expression of target genes involved in proliferation, apoptosis, cell cycle differentiation, invasion and metabolism ([@b9-or-0-0-7173]). Aberrant expression of miRNAs contributes to tumorigenesis, invasion and metastasis by derepressing or silencing key regulatory proteins in various types of tumors, including pituitary adenomas ([@b10-or-0-0-7173]--[@b12-or-0-0-7173]). Many studies have investigated the roles of miRNAs in pituitary tumorigenesis, dysfunction, neurodegeneration and metastasis by comparing tumoral to normal pituitary tissues ([@b13-or-0-0-7173]--[@b16-or-0-0-7173]). However, currently, there are few studies that have explored aggressiveness-associated miRNAs in 'aggressive' pituitary tumors, especially aggressive prolactinoma, one of the most common subtypes of pituitary adenomas, based on large-scale human tissue datasets.

In recent years, microarray technology and bioinformatic analysis have been widely used to help us discover novel clues to identify reliable and functional miRNAs. In the present study, differentially expressed miRNAs (DEMs, DE-miRNAs) between aggressive and nonaggressive prolactin pituitary tumors were screened using the GSE46294 miRNA expression profile ([@b17-or-0-0-7173]). The potential target genes of the top three most highly upregulated and downregulated DE-miRNAs were predicted by miRTarBase. Subsequently, Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment and protein-protein interaction (PPI) network analyses were performed to help us understand the molecular mechanisms underlying the aggressiveness of pituitary tumors. Finally, 20 hub genes were identified, and an miRNA-hub gene network was constructed by Cytoscape software. In conclusion, our study aimed to explore the aggressiveness-associated miRNAs in aggressive prolactin pituitary tumors and their potential molecular mechanisms based on bioinformatic analysis and to provide candidate biomarkers for early diagnosis and individualized treatment of aggressive prolactin pituitary tumors.

Materials and methods
=====================

### Microarray data

The Gene Expression Omnibus (GEO, <http://www.ncbi.nlm.nih.gov/geo/>) is a public functional genomics data repository of high-throughput gene expression data, chips and microarrays ([@b18-or-0-0-7173]). After extensive data screening in the GEO database, only the GSE46294 dataset was selected as it compared the miRNA expression of aggressive and nonaggressive prolactin pituitary tumors ([@b17-or-0-0-7173]). GSE46294, based on the GPL13264 platform (Agilent-021827 Human miRNA Microarray), contained four aggressive prolactin pituitary tumor samples and eight nonaggressive prolactin pituitary tumor samples.

### Data processing

GEO2R (<http://www.ncbi.nlm.nih.gov/geo/geo2r/>) is an interactive web tool that can compare different groups of samples from the GEO series to identify DEMs across experimental conditions ([@b19-or-0-0-7173]). The DEMs between aggressive and nonaggressive prolactin pituitary tumor samples were screened using GEO2R. Adjusted P-values (adj. P) were applied to correct the false-positive results by using the default Benjamini-Hochberg false discovery rate method. Adj. P\<0.01 and \|fold change (FC)\| \>2 were considered the cut-off values for identifying DEMs. A DEM hierarchical clustering heat map was constructed using MeV (Multiple Experiment Viewer, <http://mev.tm4.org/>), which is a cloud-based application supporting the analysis, visualization, and stratification of large genomic data, particularly RNASeq and microarray data. The potential target genes of the top three most highly upregulated and downregulated DE-miRNAs were predicted by miRTarBase (<http://mirtarbase.mbc.nctu.edu.tw/php/index.php/>), which is a database for experimentally validated miRNA-target interactions ([@b20-or-0-0-7173]).

### Functional and pathway enrichment analyses

The Database for Annotation, Visualization and Integrated Discovery (DAVID, <http://david.ncifcrf.gov/>) is an online tool for gene functional classification, which is an essential foundation for high-throughput gene analysis to understand the biological significance of genes ([@b21-or-0-0-7173]). DAVID was introduced to perform functional annotation and pathway enrichment analysis, including GO (Gene Ontology) enrichment and KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway analysis, for the predicted target genes of 6 selected DEMs ([@b22-or-0-0-7173],[@b23-or-0-0-7173]). A P-value \<0.05 was considered statistically significant.

### PPI network construction and module analysis

The target genes obtained from the upregulated and downregulated DEMs were first mapped to the STRING database (<http://string-db.org>) to assess functional associations among these target genes, with a combined score \>0.4 defined as significant ([@b24-or-0-0-7173]). Then, PPI networks were constructed using Cytoscape, which is a biological graph visualization software for integrated models of biologic molecular interaction networks ([@b25-or-0-0-7173]). The Molecular Complex Detection (MCODE) plugin of Cytoscape was used to identify the most significant module in the PPI networks ([@b26-or-0-0-7173]). The criteria for selection were as follows: Degree cut-off=2, node score cut-off=0.2, maximum depth=100 and k-core=2. Moreover, GO and KEGG enrichment analyses were performed using DAVID for genes in the modules.

### Hub gene analysis and miRNA-hub gene network construction

Hub genes were selected by considering the high degree of connectivity in the PPI networks analyzed by the cytohubba plugin of Cytoscape. The top 10 genes with the highest degree of connectivity were selected as the hub genes of the upregulated and downregulated DEMs, respectively. Subsequently, GO and KEGG enrichment analyses were performed for the selected 20 hub genes. The biological process analysis of hub genes was performed and visualized using the Biological Networks Gene Oncology tool (BiNGO) plugin of Cytoscape ([@b27-or-0-0-7173]). The latest information of functional roles of hub genes was downloaded from GeneCards in Nov. 2018 (<https://www.genecards.org/>). Subsequently, an miRNA-hub gene network was constructed by Cytoscape.

Results
=======

### Identification of DEMs and their target genes

Following analysis of the GSE46294 dataset using GEO2R, a total of 43 DEMs were identified, including 19 upregulated and 24 downregulated miRNAs between aggressive and nonaggressive prolactin pituitary tumors. For better visualization, the top 10 most highly upregulated miRNAs and the top 10 most highly downregulated miRNAs are presented in [Table I](#tI-or-0-0-7173){ref-type="table"}, and the hierarchical clustering heat map of the DEMs is presented in [Fig. S1](#SD1-or-0-0-7173){ref-type="supplementary-material"}. According to their FC values, hsa-miR-489, hsa-let-7d\* and hsa-miR-138-1\* were the top 3 most highly upregulated miRNAs, and hsa-miR-520b, hsa-miR-875-5p and hsa-miR-671-3p were the top 3 most highly downregulated miRNAs ([Table I](#tI-or-0-0-7173){ref-type="table"}). One hundred seventy potential target genes were predicted for the top 3 most highly upregulated miRNAs and 680 potential target genes were predicted for the top 3 most highly downregulated miRNAs by miRTarBase.

### Functional and pathway enrichment analyses

GO analysis, including biological process (BP), cellular component (CC) and molecular function (MF), was performed on the potential target genes of top 3 most highly upregulated miRNAs ([Table II](#tII-or-0-0-7173){ref-type="table"}) and the top 3 most highly downregulated miRNAs ([Table III](#tIII-or-0-0-7173){ref-type="table"}). GO functional annotation analysis showed that in the BP category, the target genes of the top 3 most highly upregulated miRNAs were significantly enriched in DNA-templated transcription, signal transduction, and positive regulation of transcription from RNA polymerase II promoter ([Fig. 1A](#f1-or-0-0-7173){ref-type="fig"}), while the target genes of the top 3 most highly downregulated miRNAs were enriched in DNA-templated transcription, DNA-templated regulation of transcription, and regulation of transcription from RNA polymerase II promoter ([Fig. 1B](#f1-or-0-0-7173){ref-type="fig"}). In the CC category, the target genes of the top three most highly upregulated miRNAs were significantly enriched in cytoplasm, nucleus and cytosol ([Fig. 2A](#f2-or-0-0-7173){ref-type="fig"}), while the target genes of the top three most highly downregulated miRNAs were enriched in nucleus, nucleoplasm and cytosol ([Fig. 2B](#f2-or-0-0-7173){ref-type="fig"}). In the MF category, the target genes of the top 3 most highly upregulated miRNAs were significantly enriched in protein binding, transcription factor activity, sequence-specific DNA binding, transcriptional activator activity, and RNA polymerase II core promoter proximal region sequence-specific binding ([Fig. 3A](#f3-or-0-0-7173){ref-type="fig"}), while the target genes of the top 3 most highly downregulated miRNAs were enriched in protein binding, DNA binding and transcription factor activity, and sequence-specific DNA binding ([Fig. 3B](#f3-or-0-0-7173){ref-type="fig"}). In addition, KEGG pathway analysis revealed that the target genes of the top 3 most highly upregulated miRNAs were mainly enriched in the Wnt signaling pathway, cGMP-PKG signaling pathway and renal cell carcinoma ([Fig. 4A](#f4-or-0-0-7173){ref-type="fig"}), while the target genes of the top three most highly downregulated miRNAs were mainly enriched in pathways in cancer, proteoglycans in cancer, measles and influenza A ([Fig. 4B](#f4-or-0-0-7173){ref-type="fig"}) ([Tables II](#tII-or-0-0-7173){ref-type="table"} and [III](#tIII-or-0-0-7173){ref-type="table"}).

### PPI network construction and module analysis

The PPI networks of the target genes of the top 3 most highly upregulated and downregulated DEMs were constructed ([Fig. 5](#f5-or-0-0-7173){ref-type="fig"}), and the most significant module was obtained using the MCODE plugin of Cytoscape. The genes in the most significant module of the upregulated DEMs were *SF1, SNRPD3* and *SNRPA1*, while the genes in the most significant module of the downregulated DEMs were *RNF34, RNF19B, ASB16, FBXL7, UBE2V2, RBBP6, KBTBD6, WSB1, KLHL21, CUL3, TCEB1, UBOX5* and *RNF115*. Functional analyses of the genes involved in the module of the downregulated DEMs were performed using DAVID, showing that genes in this module were mainly enriched in protein K48-linked ubiquitination (BP), polar microtubule (CC), ubiquitin-protein transferase activity (MF), and ubiquitin-mediated proteolysis(KEGG).

### Hub gene analysis and miRNA-hub gene network construction

For the upregulated miRNAs, the hub genes included *RHOB, PTPN11, SNAI2, UBE2D1, SF1, PDPN, NUP43, YY1, HIF1A* and *SNRPD3*. For the downregulated miRNAs, the hub genes were *EGFR, CTNNB1, ESR1, CDKN1A, CCND1, CYCS, DNAJC10, IL8, CUL3* and *IGF1R*. The abbreviations, full names and functions of these 20 hub genes are shown in [Table IV](#tIV-or-0-0-7173){ref-type="table"}. Among these genes, *EGFR* (epidermal growth factor receptor) demonstrated the highest node degrees, which suggested that *EGFR* may be a key target associated with prolactin pituitary tumor aggressiveness. Biological process analysis of the hub genes is shown in [Fig. 6A](#f6-or-0-0-7173){ref-type="fig"}. Functional and pathway enrichment analyses for the hub genes of the top 3 upregulated and downregulated miRNAs are presented in [Tables V](#tV-or-0-0-7173){ref-type="table"} and [VI](#tVI-or-0-0-7173){ref-type="table"}. As shown in [Fig. 6](#f6-or-0-0-7173){ref-type="fig"}, KEGG analysis showed that the hub genes of the upregulated miRNAs were mainly enriched in renal cell carcinoma and proteoglycans in cancer ([Fig. 6B](#f6-or-0-0-7173){ref-type="fig"}, [Table V](#tV-or-0-0-7173){ref-type="table"}), while the hub genes of the downregulated miRNAs were mainly enriched in proteoglycans in cancer, prostate cancer and pathways in cancer ([Fig. 6C](#f6-or-0-0-7173){ref-type="fig"}, [Table VI](#tVI-or-0-0-7173){ref-type="table"}).

Subsequently, miRNA-hub gene networks were constructed by Cytoscape ([Fig. 7](#f7-or-0-0-7173){ref-type="fig"}). As shown in [Fig. 7A](#f7-or-0-0-7173){ref-type="fig"}, hsa-miR-489, the most highly upregulated DEM, potentially could target 9 (*RHOB, PTPN11, SNAI2, UBE2D1, SF1, PDPN, NUP43, YY1* and *HIF1A*) of 10 hub genes. Five hub genes and 2 hub genes potentially were regulated by upregulated hsa-miR-138-1-3p and hsa-let-7d\*, respectively. Additionally, according to [Fig. 7B](#f7-or-0-0-7173){ref-type="fig"}, hsa-miR-520b, the most highly downregulated DEM, potentially could also target 9 (*EGFR, ESR1, CDKN1A, CCND1, CYCS, DNAJC10, IL8, CUL3* and *IGF1R*) of 10 hub genes. Three hub genes and 1 hub gene potentially were regulated by downregulated hsa-miR-875-5p and hsa-miR-671-3p, respectively. The results suggested that hsa-miR-489 and hsa-miR-520b may be the most important regulators of prolactin pituitary tumor aggressiveness.

Discussion
==========

Prolactin-secreting pituitary adenoma is the most common (30--40%) subtype of pituitary tumors and commonly presents with headache, visual disturbances, amenorrhea, galactorrhea, infertility and hyposexuality ([@b1-or-0-0-7173],[@b2-or-0-0-7173]). Most prolactinomas are noninvasive and easily treated by surgery, radiotherapy or medical treatment, including cabergoline and dopamine agonists, which are highly effective drugs for prolactinoma. However, aggressive prolactin pituitary tumors, with unknown incidence, are entities whose pathological behaviors lie between those of benign pituitary adenomas and malignant pituitary carcinomas. They display a rather distinct aggressive behavior with marked invasion of nearby anatomical structures, a tendency for resistance to conventional treatments and/or TMZ, and early postoperative recurrences ([@b3-or-0-0-7173],[@b4-or-0-0-7173]). Extensive research has been performed to explore potential biomarkers for early diagnosis and treatment of aggressive pituitary tumors. The Raf/MEK/ERK, PI3K/Akt/mTOR, and VEGFR pathways were found to be upregulated in pituitary tumors, suggesting that these pathways may be utilized to control pituitary tumor growth and progression ([@b28-or-0-0-7173]--[@b32-or-0-0-7173]). However, most targeted therapies based on the above pathways have been administered to patients with aggressive pituitary tumors without success ([@b32-or-0-0-7173]--[@b34-or-0-0-7173]). Therefore, further research is needed to discover aggressiveness-associated biomarkers with diagnostic and therapeutic value for aggressive prolactin pituitary tumors.

miRNAs are a group of small, endogenous noncoding RNAs that can repress protein expression by cleaving mRNA or inhibiting translation ([@b8-or-0-0-7173],[@b9-or-0-0-7173]). Mostly, miRNAs are recognized as having a significant role in the negative regulation of target gene expression, which contributes to tumorigenesis, invasion and metastasis in various types of tumors ([@b10-or-0-0-7173]--[@b12-or-0-0-7173]). Recent studies have shown that aberrant miRNA expression is involved in tumorigenesis and tumor development of pituitary adenomas, especially prolactin pituitary tumors ([@b13-or-0-0-7173]--[@b16-or-0-0-7173]). D\'Angelo *et al* ([@b35-or-0-0-7173]) found that miR-603, miR-34b, miR-548c-3p, miR-326, miR-570 and miR-432 were downregulated in prolactinomas, which can affect the G1-S transition process. Mussnich *et al* ([@b36-or-0-0-7173]) found that miR-15, miR-26a, miR-196a-2, miR-16, Let-7a and miR-410 were downregulated in prolactinomas, which can negatively regulate pituitary cell proliferation. Roche *et al* ([@b17-or-0-0-7173]) demonstrated that miR-183 was downregulated in aggressive prolactin tumors and inhibited tumor cell proliferation by directly targeting KIAA0101, which is involved in cell cycle activation and the inhibition of p53-p21-mediated cell cycle arrest. However, few studies, except for one reported by Roche *et al* ([@b17-or-0-0-7173]) in 2015, have been performed to explore aggressiveness-associated miRNAs in aggressive prolactin pituitary tumors based on large-scale human tissue datasets. Additionally, based on the GSE46294 dataset, our study obtained different DEMs compared with those reported by Roche *et al*. The reasons may be due to different softwares or different algorithms when analyzing differentially expressed genes or RNAs, and due to the small sample size of the GSE46294 dataset ([@b37-or-0-0-7173]).

In the present study, some aggressiveness-associated miRNAs were screened by performing a differential expression analysis based on an miRNA expression profile downloaded from the GEO database. The potential target genes of the top 3 most highly upregulated and most highly downregulated DEMs were collectively enriched for regulation of transcription from RNA polymerase II promoter, DNA-templated transcription, Wnt signaling pathway, protein binding, and transcription factor activity (sequence-specific DNA binding). Moreover, by constructing PPI networks, we identified the top 10 hub genes with the highest degree of connectivity with the top 3 most highly upregulated and downregulated DEMs. Hub genes of the upregulated DEMs were mainly enriched for proteoglycans in cancer, while hub genes of the downregulated DEMs were mainly enriched for proteoglycans in cancer, pathways in cancer, FoxO signaling pathway, and focal adhesion. Those pathways were all reported by previous studies to be associated with tumor growth, progression invasion and metastasis of various tumors ([@b38-or-0-0-7173]--[@b40-or-0-0-7173]). In our study, proteoglycan in cancer is the enriched pathway shared by both upregulated and downregulated DEMs. However, there is little research on proteoglycan in tumorigenesis, invasiveness and progression of pituitary tumors. Matano *et al* reported that endocan, a novel soluble dermatan sulfate proteoglycan, can function as a new invasion and angiogenesis marker of pituitary adenomas ([@b40-or-0-0-7173]). More studies are needed to further research the functions of proteoglycan in pituitary adenomas, especially aggressive tumors.

Among the 20 hub genes, *EGFR* demonstrated the highest node degrees, suggesting that *EGFR* was a key target associated with the aggressiveness of prolactin pituitary tumors, which is consistent with previous studies ([@b4-or-0-0-7173],[@b41-or-0-0-7173]). *EGFR* encodes a transmembrane glycoprotein that is located on the cell surface and binds to epidermal growth factor (EGF). Binding of the protein to a ligand induces receptor dimerization and tyrosine autophosphorylation, leading to cell proliferation. *EGFR* involvement in the tumorigenesis and invasion of pituitary tumors, especially aggressive prolactinomas, has been reported by previous studies, and mutations in this gene can be utilized as potential targets in the treatment of aggressive prolactinomas. As reported in the literature, tyrosine kinase inhibitors (TKIs), such as lapatanib, sunitinib and erlotinib, have been trialed as first- or second-line treatments based on the VEGFR pathway, but most of them have failed ([@b4-or-0-0-7173],[@b29-or-0-0-7173]--[@b32-or-0-0-7173],[@b34-or-0-0-7173]). In addition, in the present study, we found that *EGFR* may be negatively modulated by hsa-miR-520b using the miRTarBase database; furthermore, hsa-miR-520b can be regulated by *EGFR* due to its association with the biological process regulation of production of miRNAs involved in gene silencing by miRNA ([@b30-or-0-0-7173]--[@b32-or-0-0-7173]). This interesting finding may allow the use of this potential pathway for the diagnosis or treatment of aggressive prolactinomas in the future.

Subsequently, by constructing an miRNA-hub gene network, we found that most hub genes were potentially modulated by hsa-miR-489 and hsa-miR-520b, suggesting that these miRNAs may be the most important regulators of prolactin pituitary tumor aggressiveness. Recent studies demonstrated that hsa-miR-489 acts as a tumor suppressor in hepatocellular carcinoma ([@b42-or-0-0-7173]), gastric cancer ([@b43-or-0-0-7173]), breast cancer ([@b44-or-0-0-7173]), glioma ([@b45-or-0-0-7173]), hypopharyngeal squamous cell carcinoma ([@b46-or-0-0-7173]), bladder cancer ([@b47-or-0-0-7173]) and colorectal cancer ([@b48-or-0-0-7173]). Downregulation of miR-489 was reported to be associated with the tumorigenesis, invasion, and metastasis of various tumors, suggesting an important role for hsa-miR-489 in predicting prognosis and acting as a drug target. However, the roles of hsa-miR-489 in pituitary tumors, especially aggressive prolactinomas, have not been previously studied. Additionally, hsa-miR-520b was reported to have a suppressive effect on tumor cell proliferation, migration, invasion and epithelial-to-mesenchymal transition (EMT) in colorectal cancer ([@b49-or-0-0-7173]), glioblastoma ([@b50-or-0-0-7173]), hepatoma ([@b51-or-0-0-7173]), head-neck cancer ([@b52-or-0-0-7173]), breast cancer ([@b53-or-0-0-7173]), lung cancer ([@b54-or-0-0-7173]) and gastric cancer ([@b55-or-0-0-7173]). Expression of hsa-miR-520b is lower in tumor tissues than in normal tissues, significantly promoting the proliferation, migration, and invasion of tumor cells. Unlike other tumors, Liang *et al* ([@b56-or-0-0-7173]) reported that hsa-miR-520b was upregulated in nonfunctioning and gonadotropin-secreting pituitary adenomas relative to normal pituitaries, which indicated that miR-520b functions as a tumor inducer in benign pituitary adenoma ([@b56-or-0-0-7173]). However, whether hsa-miR-520b acts as a promoter or suppressor in aggressive prolactin pituitary tumors has not been previously studied. According to our study, we speculate that upregulation of hsa-miR-489 suppresses aggressiveness and progression, while downregulation of hsa-miR-520b promotes the aggressiveness and progression of aggressive prolactinomas. Such ambivalent miRNA expression might be one of the reasons that aggressive prolactin pituitary tumors lie on the spectrum between 'benign' pituitary adenomas and 'malignant' pituitary carcinomas. It will be extremely meaningful to authenticate the functions of hsa-miR-489 and hsa-miR-520b and elucidate the mechanisms by which they regulate aggressive behaviors, resistance to treatments and early recurrence in aggressive prolactin pituitary tumors.

There are some limitations of the present study. First, the sample size of GSE46294 is rather small (only 12 samples), which may cause some bias when identifying the differentially expressed miRNAs. Second, the expression of the differentially expressed miRNAs was not validated by RT-qPCR analysis with our clinical pituitary samples. Further studies are needed to experimentally verify the results of this study.

In conclusion, we successfully identified one key target gene, *EGFR*, and two crucial miRNAs, hsa-miR-489 and hsa-miR-520b, associated with aggressiveness based on bioinformatic analysis. These findings may provide potential candidate biomarkers for the early diagnosis and individualized treatment of aggressive prolactin pituitary tumors. However, further research is needed to experimentally verify the results of this study.
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![(A) Protein-protein interaction (PPI) network of the target genes of the top 3 most highly upregulated differentially expressed miRNAs (DEMs). (B) PPI network of the target genes of the top 3 most highly downregulated DEMs. Node size indicates the connectivity degree, and larger circles indicate a higher degree. Edge size indicates the combined scores between genes, which represent the confidence of protein interactions. The color gradually increases from dark (blue) to bright (red), representing the gradually increase in the number of interacting genes.](or-42-02-0533-g04){#f5-or-0-0-7173}

![(A) The biological process analysis of hub genes. Node color depth refers to the corrected ontology P-values. Node size indicates the number of genes involved in the ontologies. P\<0.01 was considered statistically significant. (B) Enriched Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways for the hub genes of the top 3 most highly upregulated miRNAs. (C) Enriched KEGG pathways for the hub genes of the top 3 most highly downregulated miRNAs.](or-42-02-0533-g05){#f6-or-0-0-7173}
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###### 

Top 10 upregulated and downregulated DEMs between aggressive and nonaggressive prolactin pituitary tumors.

  miRNAs (DEMs)       P-value   t       B       logFC
  ------------------- --------- ------- ------- -------
  Upregulated                                   
    hsa-miR-489       0.00677   3.25    −4.58   7.07
    hsa-let-7d\*      0.02591   2.53    −4.58   6.09
    hsa-miR-138-1\*   0.02569   2.54    −4.58   5.26
    hsa-miR-886-3p    0.00191   3.94    −4.58   4.36
    hsa-miR-576-5p    0.04773   2.2     −4.59   3.83
    hsa-miR-135b      0.01671   2.77    −4.58   3.72
    hsa-miR-137       0.03877   2.32    −4.59   3.29
    hsa-miR-886-3p    0.00235   3.82    −4.58   3.2
    hsa-miR-551b      0.02074   2.66    −4.58   3.04
    hsa-miR-296-3p    0.04524   2.23    −4.59   3.02
  Downregulated                                 
    hsa-miR-520b      0.00732   −3.21   −4.58   −6.36
    hsa-miR-875-5p    0.04037   −2.29   −4.59   −5.66
    hsa-miR-671-3p    0.01453   −2.85   −4.58   −5.49
    hsa-miR-372       0.00348   −3.61   −4.58   −5.49
    hsa-miR-586       0.02631   −2.53   −4.58   −5.44
    hsa-miR-367\*     0.02421   −2.57   −4.58   −4.84
    hsa-miR-302b      0.01052   −3.02   −4.58   −4.49
    hsa-miR-187       0.0322    −2.42   −4.59   −4.35
    hsa-miR-193b\*    0.02207   −2.62   −4.58   −4.31
    hsa-miR-452\*     0.00322   −3.65   −4.58   −4.17

miRNA names with '\*' are also mature miRNAs as annotated in miRBase (<http://www.mirbase.org>). For example, hsa-let-7d\* is hsa-let-7d-3p; hsa-miR-138-1\* is hsa-miR-138-1-3p; hsa-miR-367\* is hsa-miR-367-5p; hsa-miR-193b\* is hsa-miR-193b-5p; hsa-miR-452\* is hsa-miR-452-3p. DEMs, differentially expressed miRNAs; hsa, *Homo sapiens*.

###### 

Functional and pathway enrichment analysis for target genes of the top 3 upregulated miRNAs.

  Category             Term         Pathway description                                                                                             Count   P-value
  -------------------- ------------ --------------------------------------------------------------------------------------------------------------- ------- -------------
  Upregulated miRNAs                                                                                                                                        
  GO BP                GO:0060412   Ventricular septum morphogenesis                                                                                3       0.020464503
  GO BP                GO:0007286   Spermatid development                                                                                           4       0.021020749
  GO BP                GO:0000122   Negative regulation of transcription from RNA polymerase II promoter                                            12      0.021742388
  GO BP                GO:0006351   Transcription, DNA-templated                                                                                    24      0.022393279
  GO BP                GO:0030154   Cell differentiation                                                                                            9       0.025194909
  GO BP                GO:0097411   Hypoxia-inducible factor-1α signaling pathway                                                                   2       0.030146509
  GO BP                GO:0030177   Positive regulation of Wnt signaling pathway                                                                    3       0.030678983
  GO BP                GO:0007165   Signal transduction                                                                                             16      0.030948235
  GO BP                GO:0030336   Negative regulation of cell migration                                                                           4       0.036066871
  GO BP                GO:0045944   Positive regulation of transcription from RNA polymerase II promoter                                            14      0.03646379
  GO CC                GO:0005737   Cytoplasm                                                                                                       52      0.0134897
  GO CC                GO:0031519   PcG protein complex                                                                                             3       0.016939042
  GO CC                GO:0005634   Nucleus                                                                                                         52      0.026624876
  GO CC                GO:0005794   Golgi apparatus                                                                                                 13      0.026655792
  GO CC                GO:0005654   Nucleoplasm                                                                                                     29      0.053523267
  GO CC                GO:0031526   Brush border membrane                                                                                           3       0.054869988
  GO CC                GO:0000139   Golgi membrane                                                                                                  9       0.072820488
  GO CC                GO:0044798   Nuclear transcription factor complex                                                                            2       0.078554642
  GO CC                GO:0005829   Cytosol                                                                                                         32      0.094144731
  GO MF                GO:0005515   Protein binding                                                                                                 83      0.007060503
  GO MF                GO:0050693   LBD domain binding                                                                                              2       0.030452531
  GO MF                GO:0003700   Transcription factor activity, sequence-specific DNA binding                                                    14      0.034027538
  GO MF                GO:0001077   Transcriptional activator activity, RNA polymerase II core sequence-specific binding                            6       0.035934263
  GO MF                GO:0030620   U2 snRNA binding                                                                                                2       0.045331887
  GO MF                GO:0008517   Folic acid transporter activity                                                                                 2       0.052686367
  GO MF                GO:0001078   Transcriptional repressor activity, RNA polymerase II core promoter proximal region sequence-specific binding   4       0.054345955
  GO MF                GO:0004726   Non-membrane spanning protein tyrosine phosphatase activity                                                     2       0.059984623
  GO MF                GO:0003714   Transcription corepressor activity                                                                              5       0.071931973
  GO MF                GO:0004871   Signal transducer activity                                                                                      5       0.07295342
  KEGG                 hsa04310     Wnt signaling pathway                                                                                           5       0.006641183
  KEGG                 hsa04022     cGMP-PKG signaling pathway                                                                                      5       0.01255563
  KEGG                 hsa05211     Renal cell carcinoma                                                                                            3       0.049309583

In the event there were more than five terms enriched in this category, the top 5 terms were selected per P-value. GO, Gene Ontology; BP, biological process; CC, cellular component; MF, molecular function; KEGG, Kyoto Encyclopedia of Genes and Genomes; Count, numbers of enriched genes in each term; hsa, *Homo sapiens*.

###### 

Functional and pathway enrichment analysis for target genes of the top 3 downregulated miRNAs.

  Category               Term         Description                                                                                       Count   P-value
  ---------------------- ------------ ------------------------------------------------------------------------------------------------- ------- -------------
  Downregulated miRNAs                                                                                                                          
    GO BP                GO:0046777   Protein autophosphorylation                                                                       15      0.000170888
    GO BP                GO:0006355   Regulation of transcription, DNA-templated                                                        59      0.001639464
    GO BP                GO:0006357   Regulation of transcription from RNA polymerase II promoter                                       23      0.002882721
    GO BP                GO:0016567   Protein ubiquitination                                                                            20      0.002898481
    GO BP                GO:0006351   Transcription, DNA-templated                                                                      71      0.003602574
    GO BP                GO:0006123   Mitochondrial electron transport, cytochrome *c* to oxygen                                        4       0.014446477
    GO BP                GO:0042119   Neutrophil activation                                                                             3       0.017126856
    GO BP                GO:0007223   Wnt signaling pathway, calcium modulating pathway                                                 5       0.018278676
    GO BP                GO:0008654   Phospholipid biosynthetic process                                                                 5       0.019902891
    GO BP                GO:0048468   Cell development                                                                                  5       0.019902891
    GO CC                GO:0005654   Nucleoplasm                                                                                       112     6.68468E-07
    GO CC                GO:0005634   Nucleus                                                                                           170     0.001202665
    GO CC                GO:0017053   Transcriptional repressor complex                                                                 7       0.002719148
    GO CC                GO:0005758   Mitochondrial intermembrane space                                                                 8       0.002811554
    GO CC                GO:0005813   Centrosome                                                                                        22      0.003323275
    GO CC                GO:0005739   Mitochondrion                                                                                     50      0.006368195
    GO CC                GO:0031463   Cul3-RING ubiquitin ligase complex                                                                7       0.007248149
    GO CC                GO:0005829   Cytosol                                                                                           106     0.009417134
    GO CC                GO:0015629   Actin cytoskeleton                                                                                13      0.010602362
    GO CC                GO:0005741   Mitochondrial outer membrane                                                                      10      0.014535489
    GO MF                GO:0005515   Protein binding                                                                                   269     9.14069E-05
    GO MF                GO:0003677   DNA binding                                                                                       62      0.004456722
    GO MF                GO:0004842   Ubiquitin-protein transferase activity                                                            18      0.005935513
    GO MF                GO:0003700   Transcription factor activity, sequence-specific DNA binding                                      39      0.006954496
    GO MF                GO:0004672   Protein kinase activity                                                                           18      0.013435998
    GO MF                GO:0004879   RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding   5       0.013877869
    GO MF                GO:0003707   Steroid hormone receptor activity                                                                 6       0.015112205
    GO MF                GO:0043565   Sequence-specific DNA binding                                                                     23      0.017535243
    GO MF                GO:0031625   Ubiquitin protein ligase binding                                                                  15      0.018757483
    GO MF                GO:0004674   Protein serine/threonine kinase activity                                                          18      0.020173241
  KEGG                   hsa05162     Measles                                                                                           10      0.005987506
  KEGG                   hsa05215     Prostate cancer                                                                                   8       0.006312095
  KEGG                   hsa05200     Pathways in cancer                                                                                19      0.009215433
  KEGG                   hsa05205     Proteoglycans in cancer                                                                           12      0.011467731
  KEGG                   hsa05219     Bladder cancer                                                                                    5       0.018691786
  KEGG                   hsa04962     Vasopressin-regulated water reabsorption                                                          5       0.023655555
  KEGG                   hsa04919     Thyroid hormone signaling pathway                                                                 8       0.023895596
  KEGG                   hsa05164     Iinfluenza A                                                                                      10      0.030429321
  KEGG                   hsa05218     Melanoma                                                                                          6       0.032052212
  KEGG                   hsa04390     Hippo signaling pathway                                                                           9       0.035379929

If there were more than five terms enriched in this category, the top 5 terms were selected per the P-value. GO, Gene Ontology; BP, biological process; CC, cellular component; MF, molecular function; KEGG, Kyoto Encyclopedia of Genes and Genomes; Count, numbers of enriched genes in each term; hsa, *Homo sapiens*.

###### 

Functional roles of the hub genes of the top 3 upregulated/downregulated miRNAs identified in the PPI interaction.

  Gene symbol            Degree   Full name                                            Function
  ---------------------- -------- ---------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Upregulated miRNAs                                                                   
    *RHOB*               16       Ras homolog family member B                          Protein coding gene. Among its related pathways are ERK signaling and focal adhesion. GO annotations related to this gene include GTP binding and GDP binding.
    *PTPN11*             15       Protein tyrosine phosphatase, non-receptor type 11   Protein coding gene. Among its related pathways are immune response Fcε RI pathway and EGF/EGFR signaling pathway. GO annotations related to this gene include protein domain-specific binding and protein tyrosine phosphatase activity.
    *SNAI2*              15       Snail family transcriptional repressor 2             Protein coding gene. Among its related pathways are ERK signaling and adherens junction. GO annotations related to this gene include sequence-specific DNA binding and tran scriptional repressor activity, RNA polymerase II proximal promoter sequence-specific DNA binding.
    *UBE2D1*             14       Ubiquitin conjugating enzyme E2 D1                   Protein coding gene. Among its related pathways are gene expression and cell cycle, mitotic. GO annotations related to this gene include ligase activity and acid-amino acid ligase activity.
    *SF1*                14       Splicing factor 1                                    Protein Coding gene. Among its related pathways are Oct4 in mammalian ESC pluripotency and mRNA splicing-major pathway. GO annotations related to this gene include nucleic acid binding and RNA binding.
    *PDPN*               14       Podoplanin                                           Protein coding gene. Among its related pathways are cytoskel etal signaling and response to elevated platelet cytosolic Ca^2+^. GO annotations related to this gene include amino acid trans membrane transporter activity and folic acid transmembrane transporter activity.
    *NUP43*              13       Nucleoporin 43                                       Protein coding gene. Among its related pathways are cell cycle, mitotic and transport of the SLBP independent mature mRNA.
    *YY1*                13       YY1 transcription factor                             Protein coding gene. Among its related pathways are gene expression and translational control. GO annotations related to this gene include DNA binding transcription factor activity and transcription coactivator activity.
    *HIF1A*              11       Hypoxia inducible factor 1 subunit α                 Protein coding gene. Among its related pathways are ERK signaling and central carbon metabolism in cancer. GO anno tations related to this gene include DNA binding transcription factor activity and protein heterodimerization activity.
  *SNRPD3*               11       Small nuclear ribonu cleoprotein D3 polypeptide      Protein coding gene. Among its related pathways are mRNA splicing-major pathway and processing of capped intronless pre-mRNA. GO annotations related to this gene include histone pre-mRNA DCP binding.
  Downregulated miRNAs                                                                 
    *EGFR*               33       Epidermal growth factor receptor                     Protein coding gene. Among its related pathways are ERK signaling and gene expression. GO annotations related to this gene include identical protein binding and protein kinase activity.
    *CTNNB1*             31       Catenin β1                                           Protein coding gene. Among its related pathways are ERK signaling and focal adhesion. GO annotations related to this gene include DNA binding transcription factor activity and binding.
    *ESR1*               25       Estrogen receptor 1                                  Estrogen resistance and myocardial infarction. Among its related pathways are gene expression and integrated breast cancer pathway. GO annotations related to this gene include DNA binding transcription factor activity and identical protein binding.
    *CDKN1A*             25       Cyclin dependent kinase inhibitor 1A                 Protein coding gene. Among its related pathways are gene expression and Akt signaling. GO annotations related to this gene include ubiquitin protein ligase binding and cyclin binding.
    *CCND1*              24       Cyclin D1                                            Protein coding gene. Diseases associated with CCND1 include myeloma, multiple and Von Hippel-Lindau syndrome. Among its related pathways are ERK signaling and focal adhesion. GO annotations related to this gene include protein kinase activity and enzyme binding.
    *CYCS*               23       Cytochrome *c*, somatic                              Protein coding gene. Diseases associated with CYCS include thrombocytopenia 4 and autosomal thrombocytopenia with normal platelets. Among its related pathways are gene expression and activation of caspases through apoptosome-mediated cleavage. GO annotations related to this gene include iron ion binding and electron transfer activity.
    *DNAJC10*            21       DNAJ heat shock protein family (Hsp40) member C10    Protein coding gene. Among its related pathways are protein processing in endoplasmic reticulum. GO annotations related to this gene include chaperone binding and protein disulfide oxidoreductase activity.
    *IL8*                21       C-X-C motif chemokine ligand 8                       Protein coding gene. Among its related pathways are Akt signaling and rheumatoid arthritis. GO annotations related to this gene include chemokine activity and interleukin-8 receptor binding.
    *CUL3*               20       Cullin 3                                             Protein Coding gene. Among its related pathways are RET signaling and Class I MHC mediated antigen processing and presentation. GO annotations related to this gene include protein homodimerization activity and ubiquitin-protein trans ferase activity.
    *IGF1R*              19       Insulin like growth factor 1 receptor                Protein coding gene. Among its related pathways are ERK signaling and mTOR pathway. GO annotations related to this gene include identical protein binding and protein kinase activity.

PPI, protein-protein interaction; GO, Gene Ontology. Online database GeneCards (<https://www.genecards.org>).

###### 

Functional and pathway enrichment analysis for the hub genes of the top 3 upregulated miRNAs.

  Category             Term         Pathway description                                                                                               Genes
  -------------------- ------------ ----------------------------------------------------------------------------------------------------------------- ---------------------
  Upregulated miRNAs                                                                                                                                  
    GO BP              GO:0032364   Oxygen homeostasis                                                                                                *HIF1A*
    GO BP              GO:0032909   Regulation of transforming growth factor β2 production                                                            *HIF1A*
    GO BP              GO:0033483   Gas homeostasis                                                                                                   *HIF1A*
    GO BP              GO:0032642   Regulation of chemokine production                                                                                *SNAI2, HIF1A*
    GO BP              GO:0046885   Regulation of hormone biosynthetic process                                                                        *HIF1A*
    GO BP              GO:0043619   Regulation of transcription from RNA polymerase II promoter in response to oxidative stress                       *HIF1A*
    GO BP              GO:0070099   Regulation of chemokine-mediated signaling pathway                                                                *HIF1A*
    GO BP              GO:0032352   Positive regulation of hormone metabolic process                                                                  *HIF1A*
    GO BP              GO:0010839   Negative regulation of keratinocyte proliferation                                                                 *SNAI2*
    GO BP              GO:0071364   Cellular response to epidermal growth factor stimulus                                                             *SNAI2, PTPN11*
    GO CC              GO:0031528   Microvillus membrane                                                                                              *PDPN*
    GO CC              GO:0000243   Commitment complex                                                                                                *SNRPD3*
    GO CC              GO:0005683   U7 snRNP                                                                                                          *SNRPD3*
    GO CC              GO:0005687   U4 snRNP                                                                                                          *SNRPD3*
    GO CC              GO:0034709   Methylosome                                                                                                       *SNRPD3*
    GO CC              GO:0031527   Filopodium membrane                                                                                               *PDPN*
    GO CC              GO:0071437   Invadopodium                                                                                                      *PDPN*
    GO CC              GO:0031011   Ino80 complex                                                                                                     *YY1*
    GO CC              GO:0005685   U1 snRNP                                                                                                          *SNRPD3*
    GO CC              GO:0031258   Lamellipodium membrane                                                                                            *PDPN*
    GO MF              GO:0000400   Four-way junction DNA binding                                                                                     *YY1*
    GO MF              GO:0001227   Transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding   *YY1, SNAI2*
    GO MF              GO:0019956   Chemokine binding                                                                                                 *PDPN*
    GO MF              GO:0043565   Sequence-specific DNA binding                                                                                     *YY1, SNAI2, HIF1A*
    GO MF              GO:0061631   Ubiquitin conjugating enzyme activity                                                                             *UBE2D1*
    GO MF              GO:0000217   DNA secondary structure binding                                                                                   *YY1*
    GO MF              GO:0061650   Ubiquitin-like protein conjugating enzyme activity                                                                *UBE2D1*
    GO MF              GO:0005158   Insulin receptor binding                                                                                          *PTPN11*
    GO MF              GO:0035326   Enhancer binding                                                                                                  *YY1*
    GO MF              GO:0001078   Transcriptional repressor activity, RNA polymerase II core promoter proximal region sequence-specific binding     *YY1, SNAI2*
  KEGG                 hsa05211     Renal cell carcinoma                                                                                              *PTPN11, HIF1A*
  KEGG                 hsa05205     Proteoglycans in cancer                                                                                           *PTPN11, HIF1A*
  KEGG                 hsa04150     mTOR signaling pathway                                                                                            *HIF1A*
  KEGG                 hsa05120     Epithelial cell signaling in *Helicobacter pylori* infection                                                      *PTPN11*
  KEGG                 hsa05230     Central carbon metabolism in cancer                                                                               *HIF1A*
  KEGG                 hsa05220     Chronic myeloid leukemia                                                                                          *PTPN11*
  KEGG                 hsa04920     Adipocytokine signaling pathway                                                                                   *PTPN11*
  KEGG                 hsa04520     Adherens junction                                                                                                 *SNAI2*
  KEGG                 hsa05231     Choline metabolism in cancer                                                                                      *HIF1A*
  KEGG                 hsa04066     HIF-1 signaling pathway                                                                                           *HIF1A*

GO, Gene Ontology; BP, biological process; CC, cellular component; MF, molecular function; KEGG, Kyoto Encyclopedia of Genes and Genomes; hsa, *Homo sapiens*.

###### 

Functional and pathway enrichment analysis for the hub genes of top 3 downregulated miRNAs.

  Category               Term         Pathway description                                                                  Genes
  ---------------------- ------------ ------------------------------------------------------------------------------------ --------------------------------------------
  Downregulated miRNAs                                                                                                     
    GO BP                GO:0070141   Response to UV-A                                                                     *CCND1, EGFR*
    GO BP                GO:0097193   Intrinsic apoptotic signaling pathway                                                *CDKN1A, CUL3, DNAJC10, CYCS*
    GO BP                GO:0032355   Response to estradiol                                                                *CTNNB1, ESR1, EGFR*
    GO BP                GO:1903798   Regulation of production of miRNAs involved in gene silencing by miRNA               *ESR1, EGFR*
    GO BP                GO:0033674   Positive regulation of kinase activity                                               *CDKN1A, EGFR, IGF1R*
    GO BP                GO:0001934   Positive regulation of protein phosphorylation                                       *CDKN1A, CCND1, EGFR, IGF1R*
    GO BP                GO:0045737   Positive regulation of cyclin-dependent protein serine/threonine kinase activity     *CCND1, EGFR*
    GO BP                GO:0045740   Positive regulation of DNA replication                                               *EGFR, IGF1R*
    GO BP                GO:0006367   Transcription initiation from RNA polymerase II promoter                             *CDKN1A, CCND1, ESR1*
    GO BP                GO:0034333   Adherens junction assembly                                                           *CTNNB1*
    GO CC                GO:0030128   Clathrin coat of endocytic vesicle                                                   *EGFR*
    GO CC                GO:0030122   AP-2 adaptor complex                                                                 *EGFR*
    GO CC                GO:0030131   Clathrin adaptor complex                                                             *EGFR*
    GO CC                GO:1990907   β-catenin-TCF complex                                                                *CTNNB1*
    GO CC                GO:0005719   Nuclear euchromatin                                                                  *CTNNB1*
    GO CC                GO:0000791   Euchromatin                                                                          *CTNNB1*
    GO CC                GO:0035327   Transcriptionally active chromatin                                                   *ESR1*
    GO CC                GO:0000790   Nuclear chromatin                                                                    *CTNNB1, ESR1*
    GO CC                GO:0005758   Mitochondrial intermembrane space                                                    *CYCS*
    GO CC                GO:0016342   Catenin complex                                                                      *CTNNB1*
    GO MF                GO:0097472   Cyclin-dependent protein kinase activity                                             *CDKN1A, CCND1*
    GO MF                GO:0019900   Kinase binding                                                                       *CDKN1A, CCND1, CTNNB1, ESR1*
    GO MF                GO:0004693   Cyclin-dependent protein serine/threonine kinase activity                            *CDKN1A, CCND1*
    GO MF                GO:0004709   MAP kinase kinase kinase activity                                                    *EGFR, IGF1R*
    GO MF                GO:0001223   Transcription coactivator binding                                                    *ESR1*
    GO MF                GO:0044389   Ubiquitin-like protein ligase binding                                                *CDKN1A, CUL3, EGFR*
    GO MF                GO:0019901   Protein kinase binding                                                               *CDKN1A, CCND1, ESR1, EGFR, IGF1R*
    GO MF                GO:0030331   Estrogen receptor binding                                                            *CTNNB1, ESR1*
    GO MF                GO:0016671   Oxidoreductase activity, acting on a sulfur group of donors, disulfide as acceptor   *DNAJC10*
    GO MF                GO:0046934   Phosphatidylinositol-4,5-bisphosphate 3-kinase activity                              *ESR1, EGFR*
    KEGG                 hsa05205     Proteoglycans in cancer                                                              *CDKN1A, CCND1, ESR1, CTNNB1, EGFR, IGF1R*
    KEGG                 hsa05215     Prostate cancer                                                                      *CDKN1A, CCND1, CTNNB1, EGFR, IGF1R*
    KEGG                 hsa05200     Pathways in cancer                                                                   *CDKN1A, CCND1, CTNNB1, CYCS, EGFR, IGF1R*
    KEGG                 hsa05214     Glioma                                                                               *CDKN1A, CCND1, EGFR, IGF1R*
    KEGG                 hsa05218     Melanoma                                                                             *CDKN1A, CCND1, EGFR, IGF1R*
    KEGG                 hsa04068     FoxO signaling pathway                                                               *CDKN1A, CCND1, EGFR, IGF1R*
    KEGG                 hsa04510     Focal adhesion                                                                       *CCND1, CTNNB1, EGFR, IGF1R*
    KEGG                 hsa05213     Endometrial cancer                                                                   *CCND1, CTNNB1, EGFR*
    KEGG                 hsa05219     Bladder cancer                                                                       *CDKN1A, CCND1, EGFR*
    KEGG                 hsa05210     Colorectal cancer                                                                    *CCND1, CYCS, CTNNB1*

GO, Gene Ontology; BP, biological process; CC, cellular component; MF, molecular function; KEGG, Kyoto Encyclopedia of Genes and Genomes; hsa, *Homo sapiens*.
